Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The conference will be held in Boston from March 3-5, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings with interested parties.

Those interested in scheduling meetings can contact their institutional representative or email for details. A webcast of the presentation will be accessible through Spero Therapeutics' website on the "Events and Presentations" page under the "Connect" tab, with a replay available after the event concludes.

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45^th Annual Health Care Conference being held in Boston, March 3^rd – 5^th, 2025. Details are as follows:

TD Cowen 45th Annual Health Care Conference
Company presentation:		Wednesday March 5, 2025
Time:		3:10 PM ET

To request a meeting or for more details about the conferences please reach out to your institutional contact or email.

The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries: media@sperotherapeutics.com

FAQ

When is Spero Therapeutics (SPRO) presenting at the TD Cowen Health Care Conference?

Spero Therapeutics (SPRO) will present at the TD Cowen 45th Annual Health Care Conference in Boston from March 3-5, 2025.

Who will represent Spero Therapeutics (SPRO) at the 2025 TD Cowen conference?

Esther Rajavelu, Spero's Interim President and CEO, will represent SPRO at the TD Cowen conference in March 2025.

How can investors access Spero Therapeutics' (SPRO) presentation at the TD Cowen conference?

Investors can access SPRO's presentation via webcast through Spero's website (www.sperotherapeutics.com) on the "Events and Presentations" page under the "Connect" tab.

What therapeutic areas does Spero Therapeutics (SPRO) focus on?

Spero Therapeutics (SPRO) focuses on developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.

How can investors arrange one-on-one meetings with Spero Therapeutics (SPRO) management at the TD Cowen conference?

Investors can request one-on-one meetings with SPRO management by contacting their institutional representative or emailing the company directly.